Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Retroperitoneal fibrosis].

S Burkhardt Soares1, A Fehr, A S Brandt

  • 1Klinik für Urologie und Kinderurologie, Lehrstuhl für Urologie der Universität Witten/Herdecke, HELIOS Klinikum Wuppertal, Wuppertal. sonja.burkhardt-soares@helios-kliniken.de

Aktuelle Urologie
|May 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for New Phenomena in Final States with Two Leptons and One or No b-Tagged Jets at sqrt[s]=13  TeV Using the ATLAS Detector.

Physical review letters·2021
Same author

Search for Displaced Leptons in sqrt[s]=13  TeV pp Collisions with the ATLAS Detector.

Physical review letters·2021
Same author

Longitudinal Flow Decorrelations in Xe+Xe Collisions at sqrt[s_{NN}]=5.44  TeV with the ATLAS Detector.

Physical review letters·2021
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson Decaying into W^{±}W^{∓} or ZZ in Fully Hadronic Final States from sqrt[s]=13  TeV pp Collisions Recorded with the ATLAS Detector.

Physical review letters·2021
Same author

Medium-Induced Modification of Z-Tagged Charged Particle Yields in Pb+Pb Collisions at 5.02 TeV with the ATLAS Detector.

Physical review letters·2021
Same author

Observation and Measurement of Forward Proton Scattering in Association with Lepton Pairs Produced via the Photon Fusion Mechanism at ATLAS.

Physical review letters·2021
Same journal

[Transition in Differences of Sex Development (DSD): From Human Being to Person].

Aktuelle Urologie·2026
Same journal

[Posterior Urethral Valves: A Pediatric Urological Condition with Lifelong Relevance].

Aktuelle Urologie·2026
Same journal

[Current Developments and Strategies for Infection Prevention and Management in Penile Implant Surgery].

Aktuelle Urologie·2026
Same journal

[Transition of Patients with Neurogenic Bladder Dysfunction: Challenges and Unmet Needs in Adult Care].

Aktuelle Urologie·2026
Same journal

[Hypospadias: A Long-Term Problem?]

Aktuelle Urologie·2026
Same journal

[Urogenital Symptoms in Cyclists and Reduction of Perineal Pressure Load Using a Prostate Volume-Adapted Bicycle Saddle].

Aktuelle Urologie·2026
See all related articles

Retroperitoneal fibrosis (RPF) is a rare, potentially fatal inflammatory condition. Establishing a patient registry is crucial for developing diagnostic guidelines and effective therapies for this complex disease.

Area of Science:

  • Urology
  • Immunology
  • Rare Diseases

Context:

  • Retroperitoneal fibrosis (RPF) is a rare inflammatory condition affecting retroperitoneal structures, with an incidence of 1-2 per 200,000.
  • Currently, no established guidelines exist for RPF diagnosis or treatment, highlighting a critical gap in patient care.
  • The disease's pathogenesis remains unclear, though autoimmune processes are suspected due to associated autoimmune diseases and autoantibodies in some patients.

Purpose:

  • To address the lack of diagnostic and therapeutic guidelines for retroperitoneal fibrosis (RPF).
  • To establish a nationwide patient registry for RPF to facilitate prospective therapy trials.
  • To draft recommendations for diagnostic procedures and treatment protocols for RPF.

Summary:

  • RPF presents with localized symptoms like flank pain and leg edema due to fibrotic plaques compressing vital structures.

Related Experiment Videos

  • Laboratory findings include elevated ESR and C-reactive protein, with potential anemia.
  • Radiological imaging (CT, MRI) reveals retroperitoneal masses causing obstruction.
  • Histological examination is vital to exclude malignancy.
  • Initial treatment involves stenting and immunosuppression, with surgery or reconstructive procedures considered if medical therapy fails.

    • Impact:

    • The establishment of a nationwide patient registry is a critical step towards advancing RPF research.
    • Developing standardized diagnostic and therapeutic guidelines will improve patient outcomes.
    • Interdisciplinary and nationwide collaboration is essential for further investigation and management of this rare disease.